Temoporfin

Temoporfin
Clinical data
AHFS/Drugs.com International Drug Names
License data
ATC code L01XD05 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
Identifiers
CAS Number 122341-38-2 YesY
PubChem (CID) 60751
ChemSpider 54754
UNII FU21S769PF YesY
KEGG D06066 YesY
ChEMBL CHEMBL383675
ECHA InfoCard 100.152.970
Chemical and physical data
Formula C44H32N4O4
Molar mass 680.74 g/mol
3D model (Jmol) Interactive image
  (verify)

Temoporfin (INN) is a photosensitizer (based on chlorin) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck[1] .[2] It is marketed in the European Union under the brand name Foscan. The U.S. Food and Drug Administration (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001.[3]

Good results were obtained in 21 of 35 patients treated in Germany.[4]

It is photoactivated at 652 nm[5] i.e. by red light.

Patients can remain photosensitive for several weeks after treatment.[2]

Further reading

References

  1. Lorenz KJ, Maier H (April 2008). "[Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan]". HNO (in German). 56 (4): 402–9. doi:10.1007/s00106-007-1573-1. PMID 17516041.
  2. 1 2 O'Connor, Aisling E; Gallagher, William M; Byrne, Annette T (2009). "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochemistry and Photobiology, Sep/Oct 2009". Photochemistry and Photobiology.
  3. http://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.
  4. http://www.springerlink.com/content/g74w224824v8l013/
  5. "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy". Photochemistry and Photobiology. 2009.


This article is issued from Wikipedia - version of the 6/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.